BiOD is the lead partner for the read-out hardware and fully responsible for coordinating the commercial exploitation of the AllerScreening platform.
- RESEARCH TYPE Alzheimer diagnosis
- RESEARCH YEAR 2020
The objectives pursued by this project are two. First, validate the potential of the consortium's proprietary antibodies in early diagnosis in Alzheimer's patients. Second, obtain a first proof of concept that confirms the viability and efficacy of an immunotherapy based on those antibodies.
Alzheimer’s disease is a progressive and irreversible neurodegenerative disorder that accounts for approximately 60% to 80% of all cases of dementia and is the fifth leading cause of death worldwide. Currently, it is estimated that a total of 50 million people in all the world suffer from this disease, which has a significant impact on people’s quality of life and independence. In addition, as the population grows and life expectancy increases, the incidence and prevalence of Alzheimer’s disease is increasing.
The participants in this project have developed specific monoclonal antibodies that have an important potential to be used in the fight against Alzheimer’s disease, through two differentiated routes: a) as biomarkers for the development of new early diagnostic methods (in-vitro detection in different types of samples and novel imaging methods in PET / MRI) and b) as therapeutic agents in an immunotherapy treatment that blocks the pathological effects of the disease.
Biod will contribute to the project by providing its detection system in different media from the proprietary antibodies developed. Within this scheme, biod will mainly focus on tear detection, which will allow an agile and non-invasive diagnostic method for use in clinical practice.